Cargando…

Problems related to levodopa‐carbidopa intestinal gel treatment in advanced Parkinson's disease

BACKGROUND: Continuous levodopa‐carbidopa intestinal gel (LCIG) diminishes daily “off” time and dyskinesia in patients with advanced Parkinson′s disease (PD). Complications are common with percutaneous endoscopic gastrostomy with a jejunal extension tube (PEG‐J). AIM OF THE STUDY: To report the clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Udd, Marianne, Lyytinen, Jukka, Eerola‐Rautio, Johanna, Kenttämies, Anu, Lindström, Outi, Kylänpää, Leena, Pekkonen, Eero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516610/
https://www.ncbi.nlm.nih.gov/pubmed/28729942
http://dx.doi.org/10.1002/brb3.737
_version_ 1783251192995905536
author Udd, Marianne
Lyytinen, Jukka
Eerola‐Rautio, Johanna
Kenttämies, Anu
Lindström, Outi
Kylänpää, Leena
Pekkonen, Eero
author_facet Udd, Marianne
Lyytinen, Jukka
Eerola‐Rautio, Johanna
Kenttämies, Anu
Lindström, Outi
Kylänpää, Leena
Pekkonen, Eero
author_sort Udd, Marianne
collection PubMed
description BACKGROUND: Continuous levodopa‐carbidopa intestinal gel (LCIG) diminishes daily “off” time and dyskinesia in patients with advanced Parkinson′s disease (PD). Complications are common with percutaneous endoscopic gastrostomy with a jejunal extension tube (PEG‐J). AIM OF THE STUDY: To report the clinical outcome of LCIG in patients with advanced PD in the years 2006–2014 at Helsinki University Hospital. PATIENTS AND METHODS: Levodopa‐carbidopa intestinal gel treatment started following PEG‐J placement in patients with advanced PD after successful in‐hospital LCIG trial with a nasojejunal tube. Demographics, PEG‐J procedures, discontinuation of LCIG, complications and mortality were retrospectively analyzed. RESULTS [MEAN (SD)]: Sixty patients with advanced PD [age 68(7) years; duration of PD: 11(4) years] had LCIG treatment for 26(23) months. The majority of patients with advanced PD were satisfied with the LCIG treatment. For 51 patients (85%), the pump was on for 16 hr a day, and for nine patients (15%) it was on for 24 hr a day. After 6 months, the levodopa‐equivalent daily dose (LEDD) had increased by 30% compared to pre‐LCIG LEDD. Sixty patients underwent a total of 156 PEG‐J procedures, and 48 patients (80%) had a total of 143 complications. Forty‐six patients (77%) had 119 PEG‐J or peristomal complications, and 22 patients (37%) had a total of 25 other complications. The most common complications were accidental removal of the J‐tube in 23 patients (38%) and ≥5% weight loss in 18 patients (30%). Fifteen patients discontinued the LCIG after 21 (21) months. At the end of the follow‐up period of 33(27) months, 38 patients were still on LCIG and nine (15%) had died. CONCLUSION: Most patients were satisfied with LCIG treatment. A few patients lost weight whereas the majority had complications with PEG‐J. When LCIG treatment is carried out, neurological and endoscopic units must be prepared for multiple endoscopic procedures.
format Online
Article
Text
id pubmed-5516610
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-55166102017-07-20 Problems related to levodopa‐carbidopa intestinal gel treatment in advanced Parkinson's disease Udd, Marianne Lyytinen, Jukka Eerola‐Rautio, Johanna Kenttämies, Anu Lindström, Outi Kylänpää, Leena Pekkonen, Eero Brain Behav Original Research BACKGROUND: Continuous levodopa‐carbidopa intestinal gel (LCIG) diminishes daily “off” time and dyskinesia in patients with advanced Parkinson′s disease (PD). Complications are common with percutaneous endoscopic gastrostomy with a jejunal extension tube (PEG‐J). AIM OF THE STUDY: To report the clinical outcome of LCIG in patients with advanced PD in the years 2006–2014 at Helsinki University Hospital. PATIENTS AND METHODS: Levodopa‐carbidopa intestinal gel treatment started following PEG‐J placement in patients with advanced PD after successful in‐hospital LCIG trial with a nasojejunal tube. Demographics, PEG‐J procedures, discontinuation of LCIG, complications and mortality were retrospectively analyzed. RESULTS [MEAN (SD)]: Sixty patients with advanced PD [age 68(7) years; duration of PD: 11(4) years] had LCIG treatment for 26(23) months. The majority of patients with advanced PD were satisfied with the LCIG treatment. For 51 patients (85%), the pump was on for 16 hr a day, and for nine patients (15%) it was on for 24 hr a day. After 6 months, the levodopa‐equivalent daily dose (LEDD) had increased by 30% compared to pre‐LCIG LEDD. Sixty patients underwent a total of 156 PEG‐J procedures, and 48 patients (80%) had a total of 143 complications. Forty‐six patients (77%) had 119 PEG‐J or peristomal complications, and 22 patients (37%) had a total of 25 other complications. The most common complications were accidental removal of the J‐tube in 23 patients (38%) and ≥5% weight loss in 18 patients (30%). Fifteen patients discontinued the LCIG after 21 (21) months. At the end of the follow‐up period of 33(27) months, 38 patients were still on LCIG and nine (15%) had died. CONCLUSION: Most patients were satisfied with LCIG treatment. A few patients lost weight whereas the majority had complications with PEG‐J. When LCIG treatment is carried out, neurological and endoscopic units must be prepared for multiple endoscopic procedures. John Wiley and Sons Inc. 2017-06-05 /pmc/articles/PMC5516610/ /pubmed/28729942 http://dx.doi.org/10.1002/brb3.737 Text en © 2017 The Authors. Brain and Behavior published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Udd, Marianne
Lyytinen, Jukka
Eerola‐Rautio, Johanna
Kenttämies, Anu
Lindström, Outi
Kylänpää, Leena
Pekkonen, Eero
Problems related to levodopa‐carbidopa intestinal gel treatment in advanced Parkinson's disease
title Problems related to levodopa‐carbidopa intestinal gel treatment in advanced Parkinson's disease
title_full Problems related to levodopa‐carbidopa intestinal gel treatment in advanced Parkinson's disease
title_fullStr Problems related to levodopa‐carbidopa intestinal gel treatment in advanced Parkinson's disease
title_full_unstemmed Problems related to levodopa‐carbidopa intestinal gel treatment in advanced Parkinson's disease
title_short Problems related to levodopa‐carbidopa intestinal gel treatment in advanced Parkinson's disease
title_sort problems related to levodopa‐carbidopa intestinal gel treatment in advanced parkinson's disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516610/
https://www.ncbi.nlm.nih.gov/pubmed/28729942
http://dx.doi.org/10.1002/brb3.737
work_keys_str_mv AT uddmarianne problemsrelatedtolevodopacarbidopaintestinalgeltreatmentinadvancedparkinsonsdisease
AT lyytinenjukka problemsrelatedtolevodopacarbidopaintestinalgeltreatmentinadvancedparkinsonsdisease
AT eerolarautiojohanna problemsrelatedtolevodopacarbidopaintestinalgeltreatmentinadvancedparkinsonsdisease
AT kenttamiesanu problemsrelatedtolevodopacarbidopaintestinalgeltreatmentinadvancedparkinsonsdisease
AT lindstromouti problemsrelatedtolevodopacarbidopaintestinalgeltreatmentinadvancedparkinsonsdisease
AT kylanpaaleena problemsrelatedtolevodopacarbidopaintestinalgeltreatmentinadvancedparkinsonsdisease
AT pekkoneneero problemsrelatedtolevodopacarbidopaintestinalgeltreatmentinadvancedparkinsonsdisease